Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at AACR Annual Meeting 2022

Page View:

AACR 2022-Medicilon.jpg

Medicilon is attending AACR from April 8th -13th in New Orleans this year. Our VP and Director of the US Business Development team will be exhibiting at Booth # 3224. We are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs. Please drop by our booth and explore. We look forward to seeing you soon and wish you safe trips!

ABOUT AACR Annual Meeting 2022

In cancer research, an influential organization aims to prevent and cure cancer through research, education, communication, and collaboration. The American Association for Cancer Research (AACR) Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Why is AACR important?

The AACR is a professional society that aims to increase public awareness about cancer, supports and publishes cancer research, hosts conferences, and scientific meetings, and provides a forum for scientists to share their findings and ideas. So AACR is essential in advancing our understanding of cancer and developing new treatments for the disease.

Immuno-oncology Pharmacodynamic Model Evaluation Platform

In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as the driving force, Medicilon has developed a sophisticated tumor immunity (immuno-oncology) drug efficacy evaluation research platform. Popular models such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibodies, siRNA, and AAV are being used for immunotherapy efficacy evaluation as well as for empowering the research process of innovative therapies.

PDX Models

Orthotopic Models

Xenograft Models

CD34+ HSC Humanized Mouse Models

PBMC Humanized Mouse Models

Syngeneic Models

#Medicilon #Cancer #tumor #AACR2022

Relevant newsRelevant news